Stryker (NYSE:SYK) Downgraded by Wall Street Zen to Hold

Key Points

• Wall Street Zen downgraded Stryker to “hold” from “buy,” although the broader analyst consensus remains “Moderate Buy,” with 19 Buy ratings, five Holds, and a $372.64 average price target.
• Stryker shares opened at $276.02, near their one-year low of $267.00 and below their 50-day and 200-day moving averages. The company has a market capitalization of approximately $105.87 billion.
• Stryker exceeded quarterly expectations, reporting $3.69 in EPS and $6.59 billion in revenue, while revenue increased 9.4% year over year. However, insiders sold approximately $118.2 million worth of stock over the past three months.

Stryker (NYSE:SYK - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Saturday, Wall Street Zen reports.

Several other equities analysts also recently issued reports on SYK. Raymond James Financial set a $370.00 price target on shares of Stryker in a research note on Friday, July 31st. Argus set a $370.00 price objective on Stryker in a report on Thursday, July 9th. Wolfe Research lowered Stryker from an "outperform" rating to a "peer perform" rating in a research report on Thursday, August 13th. Royal Bank Of Canada lowered their target price on Stryker from $435.00 to $420.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Stryker in a report on Friday, July 31st. Nineteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Stryker has an average rating of "Moderate Buy" and a consensus price target of $372.64.

Stryker Stock Performance

Stryker stock opened at $276.02 on Friday. The business has a 50 day moving average of $310.77 and a 200-day moving average of $316.63. The company has a market capitalization of $105.87 billion, a P/E ratio of 28.60, a P/E/G ratio of 1.73 and a beta of 0.78. Stryker has a 1 year low of $267.00 and a 1 year high of $392.55. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period last year, the company earned $3.13 EPS. The firm's revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts predict that Stryker will post 14.97 earnings per share for the current year.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 50,000 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director directly owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. This trade represents a 2.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Dylan Crotty sold 441 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider owned 6,102 shares of the company's stock, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 351,267 shares of company stock worth $118,197,701 over the last three months. 4.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in SYK. Amundi increased its stake in Stryker by 18.3% in the second quarter. Amundi now owns 1,246,353 shares of the medical technology company's stock valued at $392,402,000 after purchasing an additional 192,447 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Stryker by 8.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company's stock worth $270,642,000 after purchasing an additional 65,333 shares in the last quarter. Veritas Asset Management LLP bought a new position in shares of Stryker during the 2nd quarter worth about $168,057,000. Rakuten Investment Management Inc. acquired a new stake in shares of Stryker in the 2nd quarter valued at about $18,646,000. Finally, Bank of America Corp DE acquired a new stake in shares of Stryker in the 2nd quarter valued at about $1,404,284,000. 77.09% of the stock is owned by institutional investors and hedge funds.

About Stryker

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used in hospitals, surgical centers and other healthcare settings. Founded in 1941 by Dr. Homer Stryker in Kalamazoo, Michigan, the company has grown from an orthopedic device business into a diversified provider of medical technologies.

Stryker's product portfolio includes orthopedic implants and instruments, surgical equipment, neurovascular devices, spine products, patient-handling and emergency-care equipment, operating-room systems, and digital and robotic technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.